Sanofi, the France-based pharmaceutical group, has entered a new collaboration with Earendil Labs, a Helixon Therapeutics–affiliated biotech, to advance bispecific antibody programmes targeting autoimmune and inflammatory diseases. The agreement strengthens Sanofi’s life sciences research pipeline by combining biologics expertise with artificial intelligence-enabled drug discovery.

The partnership could be worth up to $2.56 billion (€2.35 billion) in total milestone and development payments. Under the deal, Sanofi will use Earendil Labs’ AI-powered discovery platform to support the identification and optimisation of multiple bispecific antibody assets aimed at complex immune-mediated conditions.

Bispecific antibodies are emerging as a critical growth area within the pharma and life sciences sector, offering the potential to engage two biological targets simultaneously. The collaboration reflects ongoing industry efforts to shorten development timelines and improve therapeutic precision through advanced computational technologies.

Earendil’s platform integrates predictive protein modelling with high-throughput experimental validation. According to the company, this approach is designed to improve the efficiency of candidate selection while enhancing the efficacy profile of novel bispecific antibodies.

Jian Peng, CEO of Earendil Labs, said the technology “can assist in identifying new bispecifics and optimising their efficacy”. The platform is positioned to support scalable discovery across multiple autoimmune and inflammatory disease pathways, areas where demand for differentiated biologics continues to rise.

For Sanofi, the agreement builds on a broader strategy to embed artificial intelligence across its research and development operations. By partnering with specialist biotech platforms, the company aims to accelerate early-stage discovery while managing the growing complexity of biologic drug design.

The deal also highlights the increasing role of AI-native biotechs within the global pharma ecosystem, as large pharmaceutical groups seek external innovation to strengthen pipelines in competitive therapeutic areas. 

Read the full story of Sanofi’s latest AI-driven antibody partnership and its implications for biopharma innovation.

(Photo Credits to Shutterstock)